Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2012

View Archived Issues

Novel cytochrome P450 inhibitors patented by German university

Research in Korea yields new HIF1-alpha inhibitors

Ardelyx describes novel phosphate transport inhibitors

Pfizer describes novel antiandrogen for castration-resistant prostate cancer

High-risk prostate carcinoma-related death linked to miR-221 expression

Bionomics commences phase I/II trial of vasculature-disrupting agent in ovarian cancer

Genmab receives Arzerra milestone payment

In vivo results presented for new antibody-drug conjugate

Novel treatments for Parkinson's disease prepared at Merck & Co.

Scientists at Nektar Therapeutics present new polymer-GLP-1 conjugates

Morphotek produces novel monoclonal antibodies for cancer

Merck & Co. describes novel protein kinase inhibitors

Rigel presents preclinical data for new antiasthma drug candidate

Anti-IL10 receptor monoclonal antibody enhances BCG antitumor responses

XenoPort submits IND for potential multiple sclerosis treatment

Second cohort opens enrollment in ATOMIC-AHF trial

Lucigen receives NIH grant for RNA-based diagnostic

Kancera's ROR inhibitors show activity against fludarabine-resistant CLL

Oryzon set to begin preclinical development of hematological cancer drug

Chugai files for approval in Japan of pertuzumab

PharmaGap conditionally approves offer for GAP-107B8 license

IMI launches public-private research program to combat antibiotic resistance

Shionogi obtains additional approvals for carbapenem-type antibiotic in Japan

FDA advisory committee votes on Pfizer's data package for TTR stabilizer

RetroSense Therapeutics obtains guidance for lead biologic for eye diseases

AstraZeneca obtains approval for Inderal for new indication in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...